Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2020 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies

NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...
March 11, 2020 08:01 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome

NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
January 22, 2020 07:30 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
August 22, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces FDA Acceptance of IND Application for SLS-005 for Mucopolysaccharidosis Type III (Sanfilippo Syndrome)

NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, is pleased to announce the acceptance of the Investigation New Drug...
August 06, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Ring Opening Bell at Nasdaq on August 12th

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that Raj Mehra, PhD, Chairman, Founder, and CEO of...
August 01, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Reports Q2 2019 Pipeline Update

NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made...
July 17, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005

NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug...
May 14, 2019 08:00 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)

NEW YORK and CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed...
February 08, 2018 14:00 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA

ABO-102 results presented at WORLDSymposium for Lysosomal Diseases show significant time- and dose-dependent reduction of underlying disease pathology, including decreased CSF and urine GAGs (HS...
February 07, 2018 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial

First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB.ABO-101 is well tolerated and demonstrates...

Next Page keyboard_arrow_right